Martin Dekker Net Worth

The estimated Net Worth of Martin Dekker is at least 413 千$ dollars as of 9 December 2022. Mr. Dekker owns over 25,500 units of Bellerophon Therapeutics Inc stock worth over 1,020$ and over the last 9 years he sold BLPH stock worth over 0$. In addition, he makes 412,083$ as Vice President - Engineering and Manufacturing at Bellerophon Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Dekker BLPH stock SEC Form 4 insiders trading

Martin has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 25,500 units of BLPH stock worth 1,020$ on 9 December 2022.

The largest trade he's ever made was exercising 25,500 units of Bellerophon Therapeutics Inc stock on 9 December 2022 worth over 1,020$. On average, Martin trades about 1,500 units every 0 days since 2016. As of 9 December 2022 he still owns at least 25,500 units of Bellerophon Therapeutics Inc stock.

You can see the complete history of Mr. Dekker stock trades at the bottom of the page.

Martin Dekker biography

Martin Dekker serves as Vice President - Engineering and Manufacturing of the Company. Mr. Dekker held several positions at Spacelabs Healthcare, a company that develops and manufactures medical devices, from November 1998 to January 2015, most recently as Director of Global Operations Engineering. During his time at Spacelabs Healthcare, Mr. Dekker led and co-designed new products, developed and launched transformative manufacturing technologies and championed cross-functional quality/engineering projects. He is a member of the Institute of Electrical and Electronic Engineers. Mr. Dekker received a B.S. in electronics from Noordelijke Hogeschool Leeuwarden, the Netherlands.

What is the salary of Martin Dekker?

As the Vice President - Engineering and Manufacturing of Bellerophon Therapeutics Inc, the total compensation of Martin Dekker at Bellerophon Therapeutics Inc is 412,083$. There are 4 executives at Bellerophon Therapeutics Inc getting paid more, with Fabian Tenenbaum having the highest compensation of 1,400,000$.

How old is Martin Dekker?

Martin Dekker is 47, he's been the Vice President - Engineering and Manufacturing of Bellerophon Therapeutics Inc since 2015. There are 10 older and 7 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.

What's Martin Dekker's mailing address?

Martin's mailing address filed with the SEC is 20 INDEPENDENCE BLVD., SUITE 402, WARREN, NJ, 07059.

Insiders trading at Bellerophon Therapeutics Inc

Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over 8,853,497$ worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth 57,370,250$ . The most active insiders traders include Robert Nelsen、Adam Weinstein、Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of 10,679$. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth 107,684$.

What does Bellerophon Therapeutics Inc do?

bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.

Complete history of Mr. Dekker stock trades at Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc executives and stock owners

Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include:

• Fabian Tenenbaum,
  Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director
• Peter Fernandes,
  Chief Regulatory and Safety Officer
• Assaf Korner,
  Chief Financial Officer, Secretary
• Peter Fernandes M. Pharm,
  Interim Principal Exec. Officer, Chief Regulatory & Safety Officer
• Martin Dekker,
  Vice President - Engineering and Manufacturing
• Jonathan Peacock,
  Chairman of the Board
• Crispin Teufel,
  Independent Director
• Mary Cloyd,
  Independent Director
• Naseem Amin,
  Independent Director
• Andre Moura,
  Independent Director
• Theodore Wang,
  Independent Director
• Scott Bruder,
  Independent Director
• Matthew Bennett,
  Independent Director
• Wassim Fares,
  Chief Medical Officer.
• Amy Edmonds,
  Vice President - Clinical Operations and Administration
• Parag Shah,
  Vice President - Business Operations
• Dr. Edwin L. Parsley,
  Acting Chief Medical Officer
• Dr. Parag Suresh Shah,
  VP of Bus. Operations
• Nicholas Laccona,
  Principal Financial & Accounting Officer and Sec.
• Cross Border Opportunities ...,
  
• Megan Schoeps,
  Principal Financial Officer
• Matthew S. Holt,
  Director
• Deborah Quinn,
  Chief Medical Officer
• Adam Weinstein,
  Director
• Daniel Tasse,
  Director
• Mountain Investments Ii, Ll...,
  
• Life Science Opportunities ...,
  
• Associates Iv L P Venrock M...,
  
• Associates Iv L P Venrock H...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Shah Nimi...,
  
• Associates Iv L P Venrock P...,
  
• Associates Iv L P Venrock H...,
  
• Jens Luehring,
  Director
• Venture Fund Vi Lparch Vent...,
  
• Martin Meglasson,
  Chief Scientific Officer
• Mountain Investments Ii, Ll...,
  
• Manesh Naidu,
  Chief Business Officer
• Robert Nelsen,
  Director
• North America, Inc. Linde,
  10% owner
• Amit Agrawal,
  Chief Operating Officer
• David Abrams,
  Treasurer
• R Scott Huennekens,
  Director
• Reinilde Heyrman,
  Chief Clinical Dev. Officer
• Associates Iv L Pvenrock En...,
  
• Life Science Opportunities ...,
  
• Nicholas Laccona,
  FINANCIAL OFFICER, (PFO & PAO)
• Capital Management Lp Puiss...,
  
• Life Science Opportunities ...,
  
• Bobae Kim,
  VP Reg. Affairs & Quality